Skip to main content
Sridharan Gururangan, MD, Pediatric Hematology & Oncology, San Mateo, CA

SridharanGururanganMDF.R.C.P (Edin)

Pediatric Hematology & Oncology San Mateo, CA

Pediatric Neuro-Oncology

Senior Director, Early Clinical Development, BeiGene USA

Dr. Gururangan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gururangan's full profile

Already have an account?

Summary

  • I am board -certified in pediatric hematology-oncology and Neuro-oncology, practice pediatric neuro-oncology full-time, and deeply committed to finding the best treatment options for children with brain tumors. My clinical research involves developing novel therapies through a vigorous interaction with laboratory scientists to translate new discoveries from the lab to the clinic. I am also working to understand why certain treatments do not work and how to improve upon on treatment failures.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1996 - 1999
  • University of Tennessee
    University of TennesseeFellowship, Pediatric Hematology/Oncology, 1993 - 1994
  • University of Tennessee
    University of TennesseeResidency, Pediatrics, 1992 - 1993
  • University of Tennessee
    University of TennesseeFellowship, Pediatric Hematology/Oncology, 1991 - 1992
  • Stanley Medical College SMC
    Stanley Medical College SMCClass of 1981
  • Loyola College
    Loyola CollegeB.S., Chemistry, 1976

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2023 - 2025
  • FL State Medical License
    FL State Medical License 2015 - 2024
  • LA State Medical License
    LA State Medical License 2020 - 2022
  • NC State Medical License
    NC State Medical License 1999 - 2016
  • TN State Medical License
    TN State Medical License 1994 - 1998
  • AR State Medical License
    AR State Medical License 1993 - 1997
  • AL State Medical License
    AL State Medical License 1993 - 1994
  • American Board of Pediatrics Pediatric Hematology-Oncology
  • Royal College of Physicians, Edinburgh, ScotlandF.R.C.P (Edin)
  • Royal College of Physicians, United KingdomM.R.C.P (U.K.)
  • United College of Neurologic SpecialitiesNeuro-Oncology
  • Join now to see all

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2011-2014
  • America's Top Doctors for Cancer Castle Connolly, 2010-2012
  • Shining Star Award Make-A-Wish, Eastern North Carolina Chapter, 2009, 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Heterogeneity Within the PF-EPN-B Ependymoma Subgroup  
    Andrew Grossbach, Vijay Ramaswamy, Benjamin Lu, Mariarita Santi, Caterina Giannini, Linda M Liau, Terri S Armstrong, Sarah Leary, Matthias A Karajannis, Kenneth Aldape..., Acta Neuropathologica
  • Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation  
    Han K, Peyret T, Quartino A, Gosselin NH, Gururangan S, Casanova M, Merks JH, Massimino M, Grill J, Daw NC, Navid F, Jin J, Allison DE, Br J Clin Pharmacol, 1/1/2016
  • Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study  
    Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, G..., Childs Nerv Syst, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A prospective phase II study to determine the efficacy of GDC 0449 (Vismodegib) in adults with recurrent medulloblastoma (MB)- a pediatric brain tumor consortium study...
    Gajjar A, Gururangan S, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Fouladi M, Takebe N, Li S, Ellison D, Curren T, Gilbertson R, Boyett J, Am Assoc Cancer Res, 1/1/2013
  • Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average risk or high risk medulloblastoma.
    Gurney J G, Bass J K, Onar-Thomas Arzu, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath J A, Kellie S, Cohn R, Fisher M J, Pai-Panandiker Atmaram, ..., Proc Am Soc Clinical Oncol, 1/1/2013
  • Corcordance between the Chang and the International Society of Pediatrics Oncology (SIOP) ototoxcity grading scales in medulloblastoma patients treated with cisplatin.
    Bass J K, Huang J, Onar-Thomas A, Chang K W, Bhagat S P, Chintagumpala M, Bartels U, Gururangan S, Hassel T, Heath J, McCowage G, Cohn R J, Fisher M J, Robison G, Bron..., Proc Am Soc Clinical Oncol, 1/1/2013
  • Join now to see all

Lectures

  • Principles of Anti-Angiogenic Therapies in Brain Tumors 
    1/1/2012
  • Overview of Pediatric Brain Tumors 
    Multiple Locations, 2001, 2002, 2003, 2005, 2007, 2012 - 1/1/2012
  • Low Grade Gliomas in Children 
    1/1/2011
  • Join now to see all

Committees

  • Member, Cancer Protocol Review Committee, Duke Cancer Institute 2013 - Present
  • Member, Appointments & Promotions Committee, Duke University 2012 - Present
  • Member, Data Safety Monitoring Board, St. Jude Children's Research Hospital 2012 - Present
  • Vice-Chair, Safety Oversight Committee, Duke Cancer Institute 2004 - Present
  • Principal Investigator, Steering Committee, Pediatric Brain Tumor Consortium 2004 - Present

Other Languages

  • Tamil

Industry Relationships

  • Consultant, Biomarin2014 - Present
  • Consultant, Advanced Medical2010 - Present
  • Consultant, Boeheringer-IngenheimDrug development2009 - 2011
  • Consultant, Biologics, Inc.,
  • Consultant, NovartisHelped with drug development